In adrenocortical tumors, malignancy is strongly associated with insulin-like growth factor II (IGF-II) gene overexpression and abnormalities at the 11p15 locus, suggesting a role for this growth factor in adrenocortical tumorigenesis. To further investigate this role, the IGF/IGF-binding protein (IGFBP) system was analyzed in 18 adrenocortical tumors, classified into 2 groups on the basis of their IGF-II messenger ribonucleic acid (mRNA) content (group 1, normal IGF-II mRNA content, mostly benign tumors; group 2, high IGF-II mRNA content, mostly malignant tumors).
blotting as IGFBP-3, a band at 32 kDa, and bands at 29 -30 and 24 kDa. Total IGFBP-3 protein levels were similar in the two groups of tumors. By contrast, malignant tumors differed from benign ones by specific expression of the 32-kDa IGFBP. Immunoblotting identified this 32-kDa band together with a proteolytic fragment of 25 kDa as IGFBP-2, and quantitative analysis showed significantly higher levels of total IGFBP-2 in malignant tumors than in benign tumors (P Ͻ 0.001). Despite enhanced levels of IGBP-2 protein in malignant tumors, no increase in IGFBP-2 mRNA levels was detected, suggesting post-transcriptional regulation of this IGFBP.
These results confirm the major role of IGF-II in adrenocortical tumorigenesis and suggest that IGFBP-2 may be a regulator of IGF-II proliferative effects in this tumor system. (J Clin Endocrinol Metab 83: 1713-1720, 1998)
I NSULIN-LIKE growth factors I and II (IGF-I and IGF-II)
are structurally related polypeptides with multiple endocrine and para/autocrine activities (1) . IGF-I, IGF-II, and their receptors have been identified in the adrenal cortex, and both of these growth factors are involved in the growth and differentiation of adrenals (2, 3) . For instance, IGF-II is highly expressed in fetal adrenals, where it has proliferative effects, and both IGFs regulate steroidogenesis in adrenocortical cells (3) (4) (5) (6) (7) (8) . A role for IGF-II in adrenocortical tumorigenesis has also been suggested (9 -11) . Previous studies have shown that overexpression of the IGF-II gene, rearrangements at the 11p15 locus, and high levels of the IGF-I receptor are associated with adrenocortical malignancy (9 -12) . However, posttranscriptional regulation of IGF-II protein expression may occur in tumor tissues, such as in Wilms' tumor, in which the increase in IGF-II messenger ribonucleic acid (mRNA) is not reflected by a corresponding increase in protein levels (13) . Thus, determination of the amounts of IGF-II protein in adrenocortical tumors is an important step in analyzing the causal relationship between IGF-II and the growth of these tumors. The biological effects of IGFs are modulated in vivo by IGF-binding proteins (IGFBPs). Six IGFBPs with a high affinity for IGFs have been described (14) . They positively or negatively regulate the effects of IGF depending on their abundance and affinity for the growth factors (14) . Knowledge of the expression profile of IGFBP, therefore, is essential for understanding the effects of IGFs.
In human adult adrenocortical cells, Western ligand blotting revealed five secreted IGFBPs with apparent molecular weights of 39 -44, 34, 29 , and 24 kDa; the 39 -44 kDa doublet being identified as IGFBP-3 (15, 16) . A similar profile has been found in conditioned medium from human fetal adrenocortical cells (2) . In this model, ACTH did not regulate the expression of the IGFBPs, in contrast to the findings in adult bovine adrenocortical cells (17, 18) . IGFBP mRNA expression has also been described in normal human adrenals (2), showing different IGFBP mRNA profiles in fetal and adult adrenocortical glands. In contrast to these reports on normal human adrenals, nothing is known about the expression of IGFBPs and their possible role(s) in adrenocortical tumors.
In the present work, we investigated some as yet unknown aspects of the IGF/IGFBP system in adrenocortical sporadic tumors. We determined the amounts of IGF-II protein in 18 adrenocortical tumors with normal or high IGF-II mRNA levels. We report here elevated content of this growth factor in malignant tumors compared to that in benign ones. We also analyzed the expression of various IGFBPs and found an enhanced IGFBP-2 content in adrenocortical tumors overexpressing the IGF-II gene. This suggests that IGFBP-2 may regulate IGF-II effects in malignant adrenocortical tumors.
Subjects and Methods Patients
Eighteen patients, aged 16 -69 yr, were included in this study. Tumors were defined as benign, suspect, or malignant and grouped on the basis of IGF-II mRNA expression, measured by dot blot and Northern blot assays, and compared to normal adult adrenocortical tissue (Table  1) (11) . Each group (group 1, normal IGF-II gene expression; group 2, IGF-II gene overexpression) contained nine patients. A normal human adrenal gland was obtained from a patient who underwent large nephrectomy for kidney cancer. Tissue fragments were frozen immediately after surgery in liquid nitrogen and stored at Ϫ80 C until protein and RNA extractions.
Protein extraction
Proteins were extracted as previously described (19) . Frozen tissues (average weight, 100 -300 mg) were quickly homogenized on ice in 3 mL ice-cold 1 mol/L acetic acid containing protease inhibitors (1 mmol/L ethylenediamine tetraacetate, 1 mmol/L phenylmethylsulfonylfluoride, 1 g/mL leupeptin, 1 g/mL pepstatin, 1 g/mL aprotinin, and 3 mol/L antipain) using a Brinkmann Polytron (Brinkmann Instruments, Westbury, NY). The homogenates were incubated for 1 h at 0 C and centrifuged at 13,000 rpm for 15 min at 4 C. The supernatant was removed and saved, and the pellet was washed twice in homogenization buffer. The supernatants obtained at each step were pooled and frozen at Ϫ80 C. Aliquots of supernatant were saved for protein determination (Bio-Rad protein assay, Bio-Rad, Richmond, CA) and for IGF and IGFbinding protein assays.
IGF RIAs
IGF assays were performed as previously described (19, 20) . Lyophilized supernatants were dissolved in 1 mol/L acetic acid containing 1 mg/mL BSA (IGFBP free, Biomerieux, Paris, France) and 0.15 mol/L NaCl and centrifuged (4,000 rpm; 30 min at 0 C). The IGFs in the supernatants were then dissociated from their binding proteins by acidgel filtration on an Ultrogel AcA 54 column (IBF, Villeneuve-la-Garenne, France). At this step, the eluted fraction saved for IGF assays contained IGF-I and IGF-II of low molecular mass (7.5 kDa). IGF-I was assayed by RIA using anti-IGF-I antibodies provided by Drs. Frankenne and Hennen (Liege, Belgium). IGF-II was determined by an IGF-II protein binding assay using IGFBPs extracted from cerebrospinal fluid, as previously described (21) .
Western ligand and immunoblotting
Western ligand blotting was performed according to the method of Hossenlopp et al. (22) . Lyophilized supernatants were suspended in 100 mmol/L Tris, pH 7.5, and 200 g protein extract was submitted to SDS-11% PAGE under nonreducing conditions. Proteins were transferred to nitrocellulose and probed with a mixture of [
125 I]IGF-I and [ 125 I]IGF-II (4 ϫ 10 5 cpm each). The blots were then exposed to x-ray films for about 2 weeks at Ϫ80 C. To allow comparisons between different experiments, the same human control serum (3 L) was used for each gel.
Nitrocellulose membranes for immunoblotting were prepared as described for ligand blotting, except that electrophoresis of IGFBP-2 was performed under reducing conditions to achieve better signal resolution. Antihuman IGFBP-3 (anti-hIGFBP-3) serum (1:1000) was provided by Dr. Binoux (INSERM U-142, Paris, France). Antibovine IGFBP-2 (antibIGFBP-2) polyclonal antibodies (1:2000) were purchased from Upstate Biotechnology (Lake Placid, NY). According to the manufacturers, the anti-bIGFBP-2 antibodies show 0.1-0.5% cross-reactivity with IGFBP-1, -3, -4, and -5. For the anti-IGFBP-3 antibodies, cross-reactivity with IGFBP-1 was 1%, and no cross-reaction was found with the other IGFBPs (23) . Anti-hIGFBP-3 antibodies were incubated for 1 h at 37 C whereas anti-bIGFBP-2 antibodies were incubated overnight at 4 C. Immunoreactive proteins were visualized using the Amersham ECL System (Amersham, Aylesbury, UK).
For IGF-II immunoblotting, 250 g extracted protein were loaded on a 12.5% gel under nonreducing conditions. After transfer, the blots were probed with an antirat IGF-II monoclonal antibody (1:500) purchased from Upstate Biotechnology (Lake Placid, NY). This antibody was specific to rat and human IGF-II and showed less than 10% cross-reactivity with hIGF-I.
RNA extraction and Northern blotting
Total RNA was extracted by the CsCl/guanidine isothiocyanate method (24) . Eight micrograms of total RNA were loaded onto a 1.2% agarose-2.2 mol/L formaldehyde gel, submitted to electrophoresis, and transferred to GeneScreen Plus membrane (DuPont-New England Nuclear, Boston, MA). The membranes were baked for 2 h at 80 C to fix 
Densitometry
Western ligand blots, immunoblots, and Northern blots were analyzed by scanning with a GS700 imaging densitometer and the molecular analyst data system (Bio-Rad, Richmond, CA).
Statistical analysis
Data are expressed as the mean Ϯ sem. The two groups of tumors were compared by Mann-Whitney's U test for unpaired data, using StatView software (Abacus Concepts, Berkeley, CA). P Ͻ 0.05 was considered significant.
Results

Malignant adrenocortical tumors contain large amounts of IGF-II protein
The 18 adrenocortical tumors studied were classified into 2 groups on the basis of their IGF-II mRNA levels ( Table 1) . A strong correlation between malignancy and overexpression of the IGF-II gene has been previously described in adrenocortical tumors (9, 11) , such that group 1 tumors (normal IGF-II mRNA levels) are predominantly benign, whereas group 2 tumors (high IGF-II mRNA levels) are malignant.
IGF-I and IGF-II proteins were determined in a normal adrenal gland and for the two groups of tumors. IGF-I and IGF-II contents in the reference adrenal gland were 0.65 and 1.45 ng/mg protein, respectively. Benign tumors (group 1) had similar levels of IGF-II protein as the reference adrenal gland ( Fig. 1A ; mean, 2 Ϯ 1.1 ng/mg protein). By contrast, malignant tumors (group 2) showed a 14-fold increase in IGF-II protein content compared to the control adrenal gland (mean, 20.5 Ϯ 14.3 ng/mg protein). The difference in IGF-II protein content between benign and malignant tumors was significant at P Ͻ 0.001. This difference was specific to IGF-II, as similar levels of IGF-I protein were detected in the two groups of tumors and in the reference adrenal gland (mean, 0.65 Ϯ 0.23 and 1.06 Ϯ 0.65 ng/mg protein in groups 1 and 2, respectively).
The IGF-II assay used in this study determined mostly the mature 7.5-kDa IGF-II (21). IGF-II immunoblotting was performed on tumor extracts to determine whether other forms of the growth factor were also produced in adrenocortical tumors. Tissue extracts from hypoglycemic tumors, which produce significant amounts of big IGF-II (26), were used as controls. As shown in Fig. 1 , B and C, IGF-II species of high molecular weight (apparent molecular weight 17-24 kDa), presumably precursor forms, were detected in malignant adrenocortical tumors (tumors 14 and 16). Our failure to detect the 7.5-kDa IGF-II form in adrenocortical tumors (Fig.  1B) may be explained by the detection limit of the immunoblot method.
Malignant and benign tumors exhibit different IGFBP profiles
Ligand blotting, using a mixture of radiolabeled IGF-I and IGF-II, was used to detect functional IGFBPs, i.e. IGFBPs that have retained their binding capacity. Figure 2 shows the IGFBP profiles of normal adrenal tissue and tumors. Five different bands were detected: a major doublet of 39 -42 kDa and bands at 32, 29 -30, and 24 kDa; the 24-kDa band being fainter than the others. All of these bands were detected in the normal adrenal gland (Fig. 2) as in two other normal adrenals (data not shown). Figure 2 also shows that benign and malignant adrenocortical tumors exhibited different IGFBP profiles. Densitometry revealed no significant difference between the two groups of tumors in the amounts of the 39-/42-kDa doublet and the 29-/30-and 24-kDa bands. By contrast, the 32-kDa band was present in malignant tumors (eight of nine tumors; group 2), but was absent in all of the benign tumors tested (n ϭ 9; group 1; Fig. 2 ).
FIG. 1. IGF-I and IGF-II protein content of normal human adrenal gland and adrenocortical tumors. A, IGF-I (‚ and OE)
and IGF-II (E and F) levels in tumor extracts and in a normal human adrenal gland were determined as described in Materials and Methods. Groups 1 (normal IGF-II mRNA content) and 2 (high IGF-II mRNA content) are described in Table 1 . The mean IGF level for each group is marked with a horizontal dash. B, IGF-II immunoblotting. Protein extracts (250 g) were separated on a 12.5% polyacrylamide gel and analyzed by immunoblotting, using a specific anti-IGF-II monoclonal antibody. The numbers correspond to the patients described in Table 1 . Recombinant human IGF-II (62.5 ng) and protein extracts from hypoglycemic tumors were used as controls. C, Tumor 14 was subjected to electrophoresis on an 11% gel for better resolution.
High levels of IGFBP-2 are present in malignant adrenocortical tumors
Human polyclonal antibodies specific for IGFBP-2 and IGFBP-3 were used to detect these proteins in adrenocortical tumor extracts (Figs. 3A and 4A ).
IGFBP-2 antibodies revealed a 32-/34-kDa doublet that comigrated with the intact IGFBP-2 of control sera (Fig. 3A) , and the binding activity observed at 32 kDa on ligand blots (Fig. 2 ). An additional band was detected by the antibodies at around 25 kDa, which probably corresponds to a proteolytic fragment of the protein (Fig. 3A) . Immunoreactive 32-/ 34-and 25-kDa IGFBP-2 were detected in all adrenocortical extracts examined, including those from group 1 tumors. This contrasts with the lack of functional IGFBP-2 activity in the latter tumors (see Fig. 2 ). Quantitative analysis showed that total immunoreactive IGFBP-2 was significantly higher in malignant tumors (group 2) than in benign ones (group 1) or in the reference adrenal gland (P Ͻ 0.001; Fig.  3B ).
IGFBP proteolysis may be related to the status of the tumor. However, despite high amounts of the 25-kDa IGFBP-2 fragment in malignant tumors, the extent of IGFBP-2 proteolysis, expressed as the percentage of total IGFBP-2 processed, was similar in the two groups of tumors (Fig. 3C) .
IGFBP-3 antibodies detected two glycosylated forms of intact IGFBP-3 (39-/42-kDa doublet) and a proteolytic fragment of 30 kDa similar in size to those observed in control serum (Fig. 4A) . In contrast to IGFBP-2, total IGFBP-3 content did not differ significantly in benign and malignant tumors (P ϭ 0.26; Fig. 4B) . Surprisingly, IGFBP-3 proteolysis was less important in malignant tumors than in benign ones (P Ͻ 0.05; Fig. 4C ).
Posttranscriptional regulation of IGFBP-2 probably occurs in adrenocortical tumors
We performed Northern blot analyses of RNA from adrenocortical tumors to determine whether the high IGFBP-2 protein content detected in malignant tumors results from higher mRNA levels. IGFBP-3 and IGFBP-6 mRNA levels were also investigated for comparison.
All three IGFBP mRNAs were detected in tumors and normal adrenal gland, with IGFBP-3 mRNA giving the weakest signal (Fig. 5A ). As shown in Fig. 5B , group 2 tumors did not have higher levels of IGFBP-2 mRNA than group 1 tumors or normal adrenal, although they exhibit enhanced levels of IGFBP-2 protein. Similar levels of IGFBP-3 mRNA were detected in the two tumor groups. By contrast, malignant tumors had lower levels of IGFBP-6 mRNA than benign tumors or the reference adrenal gland (Fig. 5B) .
Discussion
Previous studies have relied on IGF-II gene expression to suggest a role for this growth factor in adrenocortical tumorigenesis (9 -11) . In the present work, we further examined this possibility by measuring directly the IGF-II protein content in 18 tumors of different phenotypes. We believe this to be an important point because posttranscriptional mechanisms may regulate IGF-II expression (13) . Our data show a specific 10-fold increase in IGF-II protein content in malignant tumors, suggesting that efficient translation of IGF-II mRNAs indeed occurs in these tissues. This result is consistent with a preliminary immunohistochemical study, in which an increased intensity of IGF-II staining was detected in two adrenocortical carcinomas (9) , and provides another strong argument in favor of IGF-II involvement in adrenocortical tumorigenesis. Table 1 . The level of IGF-II gene expression in the tumors is indicated by the symbols Ϫ (normal expression; group 1) and ϩ (overexpression; group 2). A normal human serum was used as a reference. The 32-kDa band is indicated by an arrow. The IGF assay used here (21) preferentially measures the mature 7.5-kDa IGF-II peptide. However, IGF-II forms of higher molecular weight have also been described in various types of tumor (13, 26, 27) . We did detect such precursor forms of IGF-II in malignant tumors by immunoblotting. This suggests that the amounts of IGF-II protein in these tumors may be even higher than those measured by our IGF-II assay. Large amounts of high molecular weight forms of IGF-II such as those detected in adrenal tumors have also been described in other tumors overexpressing the IGF-II gene. This indicates abnormalities of IGF-II processing in these tumor tissues (13, 26 -28) . Interestingly, these precursor forms of IGF-II are the major forms extracted from human fetal adrenal cortex, suggesting that adrenal tumor cells share similarities with fetal adrenal cells (29) .
IGFBPs locally modulate IGF actions, so IGFBP expression and activity must also be studied to understand the proliferative effects of IGF-II on adrenocortical tumor cells. Western ligand and immunoblotting were thus performed to evaluate the presence of functional and immunoreactive IGFBPs in adrenocortical tumors.
Western ligand blotting detected several functional IGFBPs in adrenocortical tumor tissues: a major doublet of 39 -42 kDa identified as IGFBP-3, a band at 32 kDa corresponding to IGFBP-2, and bands at 29 -30 and 24 kDa.
The most prominent finding of our study was the specific overexpression of IGFBP-2 in tumors with high levels of IGF-II gene expression. Thus, in adrenocortical tumors, malignant phenotype is associated with specifically high levels of IGF-II and IGFBP-2. This view is supported by the observation of Logié et al. (manuscript in preparation), who detected large amounts of IGFBP-2 in culture medium from the NCIH295R cell line derived from a human adrenocortical carcinoma (30) . Although the tissues used in the present work contain various cell types, the latter observation further suggests that IGFBP-2 is produced by tumor cells themselves. The high levels of IGF-II/IGFBP-2 expression described for malignant tumors are also reminiscent of those observed in fetal adrenal glands, suggesting that the tumor cells may have dedifferentiated to a fetal state (4, 8, 31) .
Several studies have suggested that IGFBP-2 expression may be associated with malignancy (32) (33) (34) (35) , but the exact role of IGFBP-2 in adrenocortical tumor growth remains unknown. Both stimulatory and inhibitory effects of IGFBP-2 on IGF activity have been reported, depending on the model examined (36, 37) . The high levels of IGFBP-2 detected in malignant adrenocortical tumors are consistent with a stimulatory role for IGFBP-2 in this tumor model. IGFBP-2 may increase the proliferative effects of IGF-II by binding to the cell membrane or to the extracellular matrix, thus facilitating IGF-II access to its receptor (38 -40) . Proteolysis is another possible mechanism for regulating IGFBP-2/IGF-II interactions (41) (42) (43) . IGFBP-2 proteolysis indeed occurred in adrenocortical tumor extracts, and large amounts of the IGFBP-2 Table 1 . For each sample, the amount of IGFBP mRNA was corrected for the amount of 28S RNA shown in A. The mean IGFBP mRNA level for each group is marked by a horizontal dash.
proteolytic fragment were present in malignant tumors. By decreasing IGF-II affinity, IGFBP-2 proteolysis may increase IGF-II bioavailability and enhance its proliferative effects on adrenocortical tumor cells. Although it is tempting to suggest that IGFBP-2 modulates the proliferative effects of IGF-II, this remains to be demonstrated. The high levels of IGF-II and IGFBP-2 proteins in adrenocortical tumors can be interpreted differently. For instance, IGF-II and IGFBP-2 may be coregulated in these tumors, or IGF-II may regulate IGFBP-2 expression or protect IGFBP-2 from degradation, thus increasing its half-life. Further studies are required to elucidate the interactions between these two proteins.
Normal adult adrenal glands contained functional IGFBP-2, whereas no IGFBP-2 could be detected in benign adrenocortical tumors by Western ligand blotting. Cohen et al. (44) obtained similar results for benign prostatic hyperplasia, showing a significant reduction in IGFBP-2 expression in cells isolated from patients with benign prostatic hyperplasia compared to normal prostatic cells. These two observations suggest that some dysregulation of IGFBP-2 may also occur in tumors of benign phenotype.
The molecular mechanisms leading to enhanced IGFBP-2 protein levels in malignant adrenocortical tumors remain unclear. Parallel Northern and Western blot analyses revealed discrepancy between IGFBP-2 mRNA and protein levels in benign and malignant tumors. These might be explained by posttranscriptional mechanisms, such as modifications in mRNAs translation efficiency, that would lead to different expressions of IGFBP-2 in benign and malignant tumors.
The IGFBP-2 overexpression was specific to malignant adrenocortical tumors, as neither IGFBP-3 (39 -42 kDa doublet) nor the 29-/30-and 24-kDa proteins identified by Western ligand blot differed significantly between the benign and malignant groups. Preliminary experiments using specific antibodies indicated the presence of IGFBP-4, IGFBP-5, and IGFBP-6 in adrenocortical tumors, whereas IGFBP-1 was absent. However, the precise identity of the 29-/30-kDa band observed on ligand blot requires further confirmation.
In conclusion, we have performed an extensive characterization of IGF-II and IGFBPs in adrenocortical tumors. Our data confirm a major role for IGF-II in adrenocortical tumorigenesis and suggest that IGFBP-2 may be a regulator of the proliferative effects of IGF-II in this model. Further studies are needed to determine the molecular mechanisms by which IGF-II and IGFBP-2 are involved in the proliferation of adrenocortical tumor cells. Whatever the mechanisms, IGFBP-2 could represent, in concert with IGF-II, a new prognostic factor for adrenocortical tumors.
